[Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
There are gene polymorphisms which can impact on the pharmacodynamics of anticancer agents used in the treatment of colorectal cancer. It is the case for thymidylate synthase, for methylenetetrahydrofolate reductase and for UGT 1A1. Polymorphisms of UGT 1A1 are considered as potential indicators of a risk of toxicity treatment by irinotecan. Clinical trials are in progress so as to validate the clinical usefulness of these germinal genetic analyses so as to select treatments/doses adapted to individual profiles.
Milano
Gérard
G
Laboratoire d'oncopharmacologie, Centre régional de lutte contre le cancer de Nice Antoine-Lacassagne, 06189 Nice Cedex 02. gerard.milano@nice.fnclcc.fr
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics
D000970:Antineoplastic Agents